PubRank

Lance D Miller

Author PubWeight™ 95.49‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A global map of p53 transcription-factor binding sites in the human genome. Cell 2006 20.65
2 Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 2006 8.08
3 Whole-genome cartography of estrogen receptor alpha binding sites. PLoS Genet 2007 5.85
4 Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells. Genome Biol 2004 2.77
5 Conservation of gene expression signatures between zebrafish and human liver tumors and tumor progression. Nat Biotechnol 2005 2.51
6 Tracking the evolution of the SARS coronavirus using high-throughput, high-density resequencing arrays. Genome Res 2004 2.47
7 Transcriptome analysis of zebrafish embryogenesis using microarrays. PLoS Genet 2005 2.32
8 Identification of cell cycle-regulated genes in fission yeast. Mol Biol Cell 2004 2.29
9 Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther 2010 2.27
10 Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 2002 2.21
11 Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res 2006 2.02
12 Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med 2010 1.94
13 Correlation test to assess low-level processing of high-density oligonucleotide microarray data. BMC Bioinformatics 2005 1.86
14 Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers. Hepatology 2013 1.63
15 CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells. PLoS One 2009 1.52
16 CT-X antigen expression in human breast cancer. Proc Natl Acad Sci U S A 2009 1.51
17 Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. Hepatology 2005 1.48
18 Genomic profiles specific to patient ethnicity in lung adenocarcinoma. Clin Cancer Res 2011 1.45
19 Laboratory-acquired severe acute respiratory syndrome. N Engl J Med 2004 1.37
20 Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects. Cancer Res 2002 1.34
21 Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer. Cancer Res 2009 1.32
22 Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. Genome Biol 2013 1.26
23 Optimization and clinical validation of a pathogen detection microarray. Genome Biol 2007 1.18
24 In the pursuit of complexity: systems medicine in cancer biology. Cancer Cell 2006 1.15
25 Neurotensin receptor 1 determines the outcome of non-small cell lung cancer. Clin Cancer Res 2010 1.14
26 Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer. Breast Cancer Res 2007 1.11
27 Prediction of clinical outcome in multiple lung cancer cohorts by integrative genomics: implications for chemotherapy selection. Cancer Res 2009 1.10
28 A modular analysis of breast cancer reveals a novel low-grade molecular signature in estrogen receptor-positive tumors. Clin Cancer Res 2006 1.09
29 Identification of white spot syndrome virus latency-related genes in specific-pathogen-free shrimps by use of a microarray. J Virol 2003 1.08
30 Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study. BMC Med 2006 1.08
31 Functional analysis of a cell cycle-associated, tumor-suppressive gene, protein tyrosine phosphatase receptor type G, in nasopharyngeal carcinoma. Cancer Res 2008 1.07
32 YB-1, the E2F pathway, and regulation of tumor cell growth. J Natl Cancer Inst 2011 1.04
33 Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells. Mol Cancer Ther 2012 1.01
34 RAS Mutations and Oncogenesis: Not all RAS Mutations are Created Equally. Front Genet 2012 0.99
35 The regulation of SOX7 and its tumor suppressive role in breast cancer. Am J Pathol 2013 0.99
36 Yin Yang 1 plays an essential role in breast cancer and negatively regulates p27. Am J Pathol 2012 0.98
37 DEAD-box helicase DP103 defines metastatic potential of human breast cancers. J Clin Invest 2014 0.97
38 Yin Yang 1 contains G-quadruplex structures in its promoter and 5'-UTR and its expression is modulated by G4 resolvase 1. Nucleic Acids Res 2011 0.97
39 IRP2 regulates breast tumor growth. Cancer Res 2013 0.94
40 Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma. Neoplasia 2010 0.94
41 Transcriptome kinetics of arsenic-induced adaptive response in zebrafish liver. Physiol Genomics 2006 0.94
42 SOSTDC1 differentially modulates Smad and beta-catenin activation and is down-regulated in breast cancer. Breast Cancer Res Treat 2010 0.89
43 BEARR: Batch Extraction and Analysis of cis-Regulatory Regions. Nucleic Acids Res 2004 0.88
44 Monochromosome transfer and microarray analysis identify a critical tumor-suppressive region mapping to chromosome 13q14 and THSD1 in esophageal carcinoma. Mol Cancer Res 2008 0.84
45 Gene expression profiling to identify oncogenic determinants of autocrine human growth hormone in human mammary carcinoma. J Biol Chem 2005 0.83
46 Prognostic and predictive immune gene signatures in breast cancer. Curr Opin Oncol 2015 0.83
47 Comparison of clinical outcomes and genomic characteristics of single focus and multifocal glioblastoma. J Neurooncol 2014 0.82
48 LOMA: a fast method to generate efficient tagged-random primers despite amplification bias of random PCR on pathogens. BMC Bioinformatics 2008 0.81
49 Identifying gene expression changes in breast cancer that distinguish early and late relapse among uncured patients. Bioinformatics 2006 0.80
50 A gene signature in breast cancer. N Engl J Med 2007 0.77